Case Study: Fujitsu achieves secure collaboration and faster drug discovery with Mattermost

Fujitsu Customers with Biodrug Design Accelerator (BDA) use Mattermost to power secure collaboration

Fujitsu, a global information and communications technology company, faced a challenge in enabling secure and efficient collaboration for its pharmaceutical clients using its Biodrug Design Accelerator platform. These clients handle highly sensitive R&D data and required an on-premises, customizable messaging solution to consolidate information and streamline communication among diverse, specialized teams involved in the drug discovery process. They chose Mattermost as their secure collaboration hub.

By implementing the self-hosted Mattermost platform and connecting it to their accelerator via API, Fujitsu provided a single screen for drug design information and messaging. This solution increased operational efficiency, accelerated new team member onboarding, and gave Fujitsu full control to rapidly investigate and resolve any issues. Mattermost enabled secure, real-time collaboration, which helps Fujitsu's clients accelerate the drug discovery timeline.

Fujitsu